Athira Pharma

ATHA

Current ValuationThe current P/E ratio is -0.71, within the reasonable range, cheaper than 94.25% of the time in the past 1 years, and the industry ranks 92/255, the industry Median -1.30.

-0.706xP/E
Stock price--

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-54.76x148.12%$57.18B
BAYZFUSBayer Aktiengesellschaft
-24.60x--$49.64B
BAYRYUSBayer
-24.19x--$48.81B
VTRSUSViatris
-49.05x107.75%$20.15B
ELANUSElanco Animal Health
-56.44x129.36%$11.23B
AXSMUSAxsome Therap
-47.65x26.61%$9.13B
VREOFUSVIREO GROWTH INC
-129.50x--$8.69B
CURLFUSCuraleaf Holdings, Inc.
-146.98x--$7.65B
BLTEUSBelite Bio
-61.22x29.87%$6.27B
DFTXUSDefinium Therapeutics
-13.53x53.61%$4.79B
MANEUSVeraDermics
-43.65x97.44%$4.55B
EWTXUSEdgewise Therapeutics
-22.04x137.29%$4.35B
RGCUSRegencell Bioscience
-516.66x--$3.64B
AMLXUSAmylyx Pharmaceuticals
-23.14x1.76%$3.52B
TARSUSTarsus Pharmaceuticals
-69.98x205.82%$3.25B
ELVNUSEnliven Therapeutics
-29.32x6.39%$3.11B
MBXUSMBX Biosciences
-26.28x31.12%$2.74B
SUPNUSSupernus Pharma
-22.66x70.59%$2.49B
BHCUSBausch Health
-2.05x307.94%$2.25B
PHVSUSPharvaris BV
-11.01x10.70%$2.18B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.